ADMAADMA Biologics, Inc.
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+10% of shares).
Rangebound, no clear trend. Price is −15% vs its 200-day average.
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How ADMA is trading
ADMA Biologics, Inc. is −35% over the past year while the S&P 500 is +18%: 53 points behind the market. Through the fall, its own insiders bought $251K more stock than they sold.
1-year return · S&P 500 +18%
- vs 200-day average
- −15%
vs 200-day average · a clear downtrend
- RSI (14)
- 66
RSI (14) · neutral
- Below its 52-week high
- 49%
Below its 52-week high
Details›
- Last close2026-10-09
- $10.36
- 1 monthS&P 500 +2.7%
- +10%
- 1 yearS&P 500 +18%
- −35%
- 5 yearsS&P 500 +88%
- +778%
- vs 50-day average$9.56
- +8.4%
- 52-week high
- $20.38
- 52-week low
- $7.60
- Annualised volatility
- 56%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- $251K
| Year | Return |
|---|---|
| 2026 (year to date) | −43% |
| 2025 | +6.4% |
| 2024 | +279% |
| 2023 | +16% |
| 2022 | +175% |
| 2021 | −28% |
| 2020 | −51% |
| 2019 | +67% |
| 2018 | −26% |
| 2017 | −37% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 5 of 10 | +5.4% |
| Feb | 10 | 6 of 10 | +1.1% |
| Mar | 10 | 5 of 10 | +0.38% |
| Apr | 10 | 8 of 10 | +7.1% |
| May | 10 | 5 of 10 | +2.2% |
| Jun | 10 | 2 of 10 | −3.8% |
| Jul | 11 | 8 of 11 | +11% |
| Aug | 11 | 4 of 11 | +1.0% |
| Sep | 11 | 3 of 11 | −1.7% |
| Oct | 11 | 5 of 11 | −4.7% |
| Nov | 10 | 7 of 10 | +10% |
| Dec | 10 | 4 of 10 | −5.1% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.